

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

北 斗 嘉 藥 業 股 份 有 限 公 司
BAYTACARE PHARMACEUTICAL CO., LTD.*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8197)

**DECISION OF THE GEM LISTING COMMITTEE
CANCELLATION OF LISTING**

This announcement is made by Baytacare Pharmaceutical Co., Ltd.* (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on the GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 26 September 2019 (the “**Announcement**”) in relation to, amongst other matters, the seeking of the Stock Exchange’s confirmation by the Company that the Company has fulfilled the resumption conditions. Unless otherwise defined herein, capitalised terms used herein shall have the same meaning as defined in the Announcement.

DELISTING DECISION AND APPLICATION FOR REVIEW

On 15 November 2019, the Company received a letter (the “**Letter**”) from the Stock Exchange stating that since the trading in the Company’s securities has been suspended since 27 September 2018 and failed to resume trading by 26 September 2019, accordingly, the GEM Listing Committee decided to cancel the Company’s listing under Rule 9.14A of the GEM Listing Rules (the “**Delisting Decision**”). It was indicated in the Letter that the last day of listing of the Company’s shares will be on 29 November 2019 and the listing of shares of the company will be cancelled with effect from 9:00 a.m. on 2 December 2019.

After considering legal and professional advice, the Company has on 22 November 2019 submitted a written request to the secretary of the GEM Listing Review Committee of the Stock Exchange pursuant to Rule 4.06(2) of the GEM Listing Rules for a review of the Delisting Decision.

Should there be any material development(s), further announcement(s) will be made by the Company as and when appropriate and in accordance with the requirements of the GEM Listing Rules. Shareholders who have queries about the implication of the delisting of the shares of the Company are advised to seek appropriate professional advice.

CONTINUED SUSPENSION OF TRADING IN THE SHARES OF THE COMPANY

Trading in the shares of the Company has been suspended with effect from 9am on 27 September 2018, and will continue to be suspended until further notice.

By Order of the Board
Baytacare Pharmaceutical Co., Ltd.*
Executive Director
Cui Bingyan

Shenzhen, People's Republic of China, 22 November 2019

As at the date of this announcement, the executive Directors are Cui Bingyan, Fang Yao, Guo Aiqun and Zheng Chunyan; the non-executive Director is Cao Yang; and the independent non-executive Directors are Chen Youfang, Zhu Tianxiang and Zhao Xiaomei.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the website of GEM at www.hkgem.com for at least 7 days from the date of the publication and the Company's website at www.baytacare.com from the date of this announcement.

* *for identification purposes only*